Evidence map›Paper›PMID 19679220›Full record

ArticleVaccine2009

Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour.

Keng Wooi Ng, Marc Pearton, Sion Coulman, Alexander Anstey, Christopher Gateley, Anthony Morrissey, Christopher Allender, James Birchall

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. AnFrontiers in microbiology · 2019
    Article
  10. Article
  11. Review
  12. Article
  13. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept.Journal of controlled release : official journal of the Controlled Release Society · 2013
    Article
  14. Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin.Journal of controlled release : official journal of the Controlled Release Society · 2013
    Article
  15. Microneedles for drug and vaccine delivery.Advanced drug delivery reviews · 2012
    Review
  16. Microneedle delivery of plasmid DNA to living human skin: Formulation coating, skin insertion and gene expression.Journal of controlled release : official journal of the Controlled Release Society · 2012
    Article
  17. Delivery systems for intradermal vaccination.Current topics in microbiology and immunology · 2012
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Keng Wooi NgGene Delivery Research Group, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3NB, UK.
Marc Pearton
Sion Coulman
Alexander Anstey
Christopher Gateley
Anthony Morrissey
Christopher Allender
James Birchall
Cardiff University · GBRoyal Gwent Hospital · GB

Funding

Microneedle-based immunization against pandemic influenzaR01EB006369 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI PRAUSNITZ, MARK R. · 2007 to 2011
$3.6M
NIBIB NIH HHS EB006369NIBIB NIH HHS R01 EB006369
6 · The paper itself

Abstract

The presence of resident Langerhans cells (LCs) in the epidermis makes the skin an attractive target for DNA vaccination. However, reliable animal models for cutaneous vaccination studies are limited. We demonstrate an ex vivo human skin model for cutaneous DNA vaccination which can potentially bridge the gap between pre-clinical in vivo animal models and clinical studies. Cutaneous transgene expression was utilised to demonstrate epidermal tissue viability in culture. LC response to the culture environment was monitored by immunohistochemistry. Full-thickness and split-thickness skin remained genetically viable in culture for at least 72 h in both phosphate-buffered saline (PBS) and full organ culture medium (OCM). The epidermis of explants cultured in OCM remained morphologically intact throughout the culture duration. LCs in full-thickness skin exhibited a delayed response (reduction in cell number and increase in cell size) to the culture conditions compared with split-thickness skin, whose response was immediate. In conclusion, excised human skin can be cultured for a minimum of 72 h for analysis of gene expression and immune cell activation. However, the use of split-thickness skin for vaccine formulation studies may not be appropriate because of the nature of the activation. Full-thickness skin explants are a more suitable model to assess cutaneous vaccination ex vivo.

Indexed as

Organ Culture TechniquesTissue SurvivalAdultAgedEpidermal CellsFemaleGene ExpressionGene Transfer TechniquesHumansInjections, IntradermalLangerhans CellsMiddle AgedPlasmidsSkinTransgenesVaccination

Identifiers

PMID19679220
PMCPMC2753709
OpenAlexW2165933648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.